New research suggests that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who stop traditional lifestyle plans.
Published data in a prominent medical journal points out that while obese individuals often shed a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"Users purchasing such medications need to be aware of the potential of fast rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
Such speed of regain implies a return to starting weight within about 18 months.
Analyzing Therapies
The research, which reviewed 37 of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
The team note that people who shed pounds through dieting generally have a less rapid creep back—approximately 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Experts propose the way of the injections explains the amplified regain.
These medications copy a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in hunger is no longer kept in check, making binge eating much more probable."
An Ongoing Condition?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, considering the high risk of weight regain, the treatment might need to be ongoing.
This view is supported by pharmaceutical companies, who state that the results "highlight the persistent character of excess weight," similar to managing conditions like hypertension.
Patient Accounts
People who have stopped the jabs explain a intense resurgence of hunger.
"I experienced something that goes on and I was suddenly ravenous," recalled one woman.
The struggle is worsened if patients have not established sustainable lifestyle or habit changes during therapy.
Growing Adoption
Figures suggest that a significant number of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is greater among women than males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while the jabs are effective tools for shedding pounds, they are not a standalone cure and maintained weight loss hinges on integrated behavioural management.
